- Home
- APM vs SNGX Comparison
APM vs SNGX Comparison
Compare APM & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- SNGX
- Stock Information
- Founded
- APM 2010
- SNGX 1987
- Country
- APM United Kingdom
- SNGX United States
- Employees
- APM N/A
- SNGX N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- SNGX Biotechnology: Pharmaceutical Preparations
- Sector
- APM Health Care
- SNGX Health Care
- Exchange
- APM Nasdaq
- SNGX Nasdaq
- Market Cap
- APM 6.1M
- SNGX 6.5M
- IPO Year
- APM 2018
- SNGX 1987
- Fundamental
- Price
- APM $1.07
- SNGX $1.93
- Analyst Decision
- APM
- SNGX
- Analyst Count
- APM 0
- SNGX 0
- Target Price
- APM N/A
- SNGX N/A
- AVG Volume (30 Days)
- APM 81.2K
- SNGX 18.1K
- Earning Date
- APM 06-17-2025
- SNGX 05-09-2025
- Dividend Yield
- APM N/A
- SNGX N/A
- EPS Growth
- APM N/A
- SNGX N/A
- EPS
- APM N/A
- SNGX N/A
- Revenue
- APM N/A
- SNGX $2,342.00
- Revenue This Year
- APM N/A
- SNGX N/A
- Revenue Next Year
- APM N/A
- SNGX N/A
- P/E Ratio
- APM N/A
- SNGX N/A
- Revenue Growth
- APM N/A
- SNGX N/A
- 52 Week Low
- APM $0.46
- SNGX $1.68
- 52 Week High
- APM $7.49
- SNGX $14.83
- Technical
- Relative Strength Index (RSI)
- APM 58.89
- SNGX 49.95
- Support Level
- APM $0.83
- SNGX $1.86
- Resistance Level
- APM $1.35
- SNGX $1.97
- Average True Range (ATR)
- APM 0.12
- SNGX 0.09
- MACD
- APM 0.02
- SNGX 0.01
- Stochastic Oscillator
- APM 46.97
- SNGX 70.59
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in two segments: Therapeutics and Non-Therapeutics. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).